Teva Pharmaceutical (NYSE:TEVA) lost ~13%, posting what could be its biggest intraday decline since March 2020 after the generic drugmaker set its 2025 earnings outlook below consensus even as its Q4 ...

Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...

The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Janney Montgomery Scott LLC increased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 5.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

Sanofi's SNY +1.27% + Free Alerts short percent of float has risen 11.76% since its last report. The company recently ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

Sanofi (NASDAQ:SNY) said that a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment of multiple myeloma met its co-primary endpoints, demonstrating non-inferiority to ...